These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 20628126)

  • 21. Early stopping rules in oncology: considerations for clinicians.
    Mukherjee SD; Goffin JR; Taylor V; Anderson KK; Pond GR
    Eur J Cancer; 2011 Nov; 47(16):2381-6. PubMed ID: 21684153
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Data Monitoring Committees and early stopping guidelines: the Southwest Oncology Group experience.
    Crowley J; Green S; Liu PY; Wolf M
    Stat Med; 1994 Jul 15-30; 13(13-14):1391-9. PubMed ID: 7973218
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ethics of randomised controlled trials--not yet time to give up on equipoise.
    Ashcroft RE
    Arthritis Res Ther; 2004; 6(6):237-9. PubMed ID: 15535836
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comments on "Efficacy of quetiapine monotherapy in bipolar I and II depression: a double-blind, placebo-controlled study (the BOLDER II Study)" by Dr Thase and colleagues.
    Rifkin AE
    J Clin Psychopharmacol; 2008 Jun; 28(3):367; author reply 368. PubMed ID: 18480708
    [No Abstract]   [Full Text] [Related]  

  • 25. The ethics of underpowered clinical trials.
    Hughes JR
    JAMA; 2002 Nov; 288(17):2118; author reply 2119. PubMed ID: 12413366
    [No Abstract]   [Full Text] [Related]  

  • 26. From randomized trials to registry studies: translating data into clinical information.
    Brown ML; Gersh BJ; Holmes DR; Bailey KR; Sundt TM
    Nat Clin Pract Cardiovasc Med; 2008 Oct; 5(10):613-20. PubMed ID: 18679381
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Consequences of handling missing data for treatment response in osteoarthritis: a simulation study.
    Olsen IC; Kvien TK; Uhlig T
    Osteoarthritis Cartilage; 2012 Aug; 20(8):822-8. PubMed ID: 22441031
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Choice of test for comparing two groups, with particular application to skewed outcomes.
    White IR; Thompson SG
    Stat Med; 2003 Apr; 22(8):1205-15. PubMed ID: 12687651
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Alternative analyses for antiepileptic drug trials.
    Pledger GW; Sahlroot JT
    Epilepsy Res Suppl; 1993; 10():167-74. PubMed ID: 8251092
    [No Abstract]   [Full Text] [Related]  

  • 30. The clinical importance of early stopping of randomized trials in cancer treatments.
    Souhami RL
    Stat Med; 1994 Jul 15-30; 13(13-14):1293-5. PubMed ID: 7973210
    [No Abstract]   [Full Text] [Related]  

  • 31. Missing data in rheumatologic studies and the practical reality of modern approaches to the analysis of incomplete subject data: comment on the article by Baron et al and the editorial by Boers.
    Steele R; Hudson M
    Arthritis Rheum; 2008 Sep; 59(9):1367-8. PubMed ID: 18759312
    [No Abstract]   [Full Text] [Related]  

  • 32. Standardized mean differences in individually-randomized and cluster-randomized trials, with applications to meta-analysis.
    White IR; Thomas J
    Clin Trials; 2005; 2(2):141-51. PubMed ID: 16279136
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mammography studies revisited.
    Emory TH
    Minn Med; 2004 Feb; 87(2):7. PubMed ID: 15005121
    [No Abstract]   [Full Text] [Related]  

  • 34. Statistical issues in interpreting clinical trials.
    DeMets DL
    J Intern Med; 2004 May; 255(5):529-37. PubMed ID: 15078496
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Heart Protection Study and bias in the interpretation of RCTs.
    Conradi P; Taylor D
    J Eval Clin Pract; 2005 Aug; 11(4):405-7. PubMed ID: 16011653
    [No Abstract]   [Full Text] [Related]  

  • 36. On responder analyses when a continuous variable is dichotomized and measurement error is present.
    Kunz M
    Biom J; 2011 Feb; 53(1):137-55. PubMed ID: 21259314
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Equipoise, design bias and randomized controlled trials: the elusive ethics of new drugs--a comment.
    Schimetta W; Poelz G; Poelz W; Haring HP; Aichner F
    Arthritis Res Ther; 2004 Nov; 7(1):E2. PubMed ID: 15642128
    [No Abstract]   [Full Text] [Related]  

  • 38. Importance of blinding in randomized trials.
    Strite SA; Stuart ME
    JAMA; 2010 Nov; 304(19):2127-8; author reply 2128. PubMed ID: 21081725
    [No Abstract]   [Full Text] [Related]  

  • 39. Listen to the data when results are not significant.
    Hewitt CE; Mitchell N; Torgerson DJ
    BMJ; 2008 Jan; 336(7634):23-5. PubMed ID: 18174597
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The architecture of clinical research (From the "Biostatistics and Epidemiology Lecture Series, Part 1").
    Stoller JK
    Cleve Clin J Med; 2017 Sep; 84(9 Suppl 2):e2-e9. PubMed ID: 28937357
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.